EXECUTIVE INSIGHTS
DOMAIN EXPERTS
PLAYERS
PARTICIPANTS
-
SEP 2024
-
EDITION 6
-
TABLES 123
-
REGIONS 26
-
SEGMENTS 4
-
PAGES 194
-
US$ 4950
-
MCP10793
-
JOIN OUR PANEL
EXECUTIVE ENGAGEMENTS BY TIER
-
CXO
-
VICE PRESIDENT
-
DIRECTOR
-
MANAGER
-
MARKETING
© Copy rights Global Industry Analysts, Inc., USA. www.strategyr.com All Rights Reserved.
OUR EXPERT PANELS
Panelists are carefully chosen based on their domain expertise and market influence.
Participation in our expert panels is only by invitation. Our project focused panels are constituted of senior executives in business strategy, marketing, sales, and product management at competitive companies worldwide. We also welcome individuals from leading management consulting, venture capital, private equity, investment management and related firms with domain expertise and are actively monitoring specific companies or industries. Our panelists bring unique market perspectives and unbiased intelligence to our ongoing research programs.
WHY PARTICIPATE?
Expertise to the Power of YOU!
- Collaborative Insights - Expand your deep domain insights from participants at competitive companies worldwide while you share your own!
- Global Acumen Alerts - Expand your intelligence on your areas of interest by enabling our “Email Alerts” feature drawing from other influencers’ project participation.
- Enterprise-wide Project Discounts - Discounts start @ 10% and build up as more participants support our ongoing projects in your space.
- Complimentary Copies - We highly recommend collaboration with your team to draw upon their geographical domain expertise. Our platform enables collaborative engagements with 10 peers. When you or any of your team members purchase the report, the entire team will receive complimentary copies with full stack access to our data and updates for one year.
- Annual Digital Subscription to one of the business publications or $100 value gift card - No Purchase Required! The lead participant will receive the digital subscription
- The Economist
- MIT Technology Review
- Harvard Business Review
Note - Offer is limited to one participant per company. Offer may be withdrawn at anytime without notice once our annual maximum participation of leading players is fulfilled. Offer by invitation only, to enterprise executives in from companies featured in the project ranked. If you’ve received our initation, you’re qualified! If not, you may check your eligibility by registering to join our Project Expert Panel. Typically you must be have a Marketing, Strategy, Product Management or Business Development, role as a CXO or VP or Director or Manager directly involved with the P&L of the products or services covered in the report. You must complete all modules in the Primary Research Data Simulator.
MARKETGLASS
BASIC
- Annual Prepaid Subscription
- Single-User
- 10,000 Data Room Credits/Month
- Research Tool - Unlimited Access to Build Your Own Search Engine Data & Domain Expert Video Transcriptions.
- Use MarketGlassTM Data Templates For Your Own Enterprise Data to Build Bespoke Research Reports.
- My Silo - Build Your Private Data Room for Generative AI and Other Applications. Download Data Stacks For External Applications & Language Models.
PREMIUM
- Annual Prepaid Subscription
- One Research Project With One Complimentary Update/Year
- 10-User License
- 10-User Peer-to-Peer Collaborative Features
- 200 Domain Expert Insights (With Name, Company, and Date)
- 50,000 Data Room Credits
- Research Tool - Unlimited Access to Build Your Own Search Engine Data & Domain Expert Video Transcriptions.
- Use Publisher's Market Data Templates to Simulate & Build Your Bespoke Variations to Published Data (4 Reports/Year)
- Use Your Own Data and MarketGlassTM Data Room Content.
- My Silo - Build Your Private Data Room for Generative AI and Other Applications. Download Data Stacks For External Applications & Language Models.
- Add Extra Topics/Reports During The Year At Regular Prices With Full Platform Privileges
ENTERPRISE
- Annual Prepaid Subscription
- Four Research Projects With One Complimentary Update/Year
- 25-User License
- 25-User Peer-to-Peer Collaborative Engagements
- 500 Domain Expert Insights (With Name, Company, and Date)
- 150,000 Data Room Credits
- Research Tool - Unlimited Access to Build Your Own Search Engine Data & Domain Expert Video Transcriptions.
- Use Publisher's Market Data Templates to Simulate & Build Your Bespoke Variations to Published Data (4 Reports/Year)
- Use Your Own Data and MarketGlassTM Data Room Content.
- My Silo - Build Your Private Data Room for Generative AI and Other Applications. Download Data Stacks For External Applications & Language Models.
- Add Extra Topics/Reports During The Year At Regular Prices With Full Platform Privileges
HIGHLIGHTS & REPORT INDEX
Global Breast Cancer Screening Market to Reach US$8.3 Billion by 2030
The global market for Breast Cancer Screening estimated at US$5.9 Billion in the year 2023, is expected to reach US$8.3 Billion by 2030, growing at a CAGR of 5.1% over the analysis period 2023-2030. Imaging Test, one of the segments analyzed in the report, is expected to record a 5.8% CAGR and reach US$4.8 Billion by the end of the analysis period. Growth in the Immunohistochemistry Test segment is estimated at 4.6% CAGR over the analysis period.
The U.S. Market is Estimated at US$1.5 Billion While China is Forecast to Grow at 8.0% CAGR
The Breast Cancer Screening market in the U.S. is estimated at US$1.5 Billion in the year 2023. China, the world`s second largest economy, is forecast to reach a projected market size of US$1.9 Billion by the year 2030 trailing a CAGR of 8.0% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.0% and 4.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.8% CAGR.
Global Breast Cancer Screening Market - Key Trends and Drivers Summarized
Why Is Breast Cancer Screening Crucial for Early Detection?
Breast cancer screening plays a pivotal role in the early detection of breast cancer, a prevalent disease that affects millions of women worldwide. The primary goal of screening is to identify cancer in its earliest stages, even before symptoms become apparent, thus allowing for timely and potentially life-saving treatments. Techniques such as mammography, ultrasound, MRI, and genetic testing are utilized to detect abnormalities in breast tissue. Among these, mammography remains the most widely recommended and utilized method due to its ability to detect small tumors that might not be felt during a physical examination. Regular screening is especially important for women over 40 or those with a family history of breast cancer, as it can significantly reduce the risk of death from the disease by enabling earlier and more effective treatment.
How Has Technology Revolutionized Breast Cancer Screening?
The field of breast cancer screening has been significantly advanced by technological innovations, making the process more precise, less invasive, and more accessible than ever before. Digital mammography, a key development, has improved the clarity of images and allowed for better detection of minute abnormalities. This technology also facilitates easier storage and sharing of images, enabling more collaborative and informed decision-making in patient care. Furthermore, 3D mammography, or tomosynthesis, has emerged as a game-changer by providing a multi-dimensional view of breast tissue, which reduces false positives and improves the accuracy of diagnoses. The incorporation of artificial intelligence (AI) into the screening process is another transformative leap, with AI tools now capable of assisting radiologists in identifying subtle signs of cancer that might otherwise be overlooked. These technological advancements are not only enhancing the accuracy of breast cancer screening but are also making the process more efficient, thereby improving outcomes for patients.
What New Trends Are Shaping the Future of Breast Cancer Screening?
The landscape of breast cancer screening is rapidly evolving, with several new trends setting the stage for the future of this critical healthcare service. A prominent trend is the move towards personalized screening approaches, where individual risk factors such as genetics, age, and breast density are taken into account to tailor screening protocols. This personalized approach seeks to maximize the effectiveness of screening while reducing the risks associated with overdiagnosis and unnecessary treatments. Another emerging trend is the increasing use of advanced imaging technologies like contrast-enhanced mammography and breast MRI, which offer more detailed visualization and are particularly beneficial for individuals at higher risk. The integration of AI into screening procedures is also gaining traction, providing radiologists with advanced tools to improve diagnostic accuracy and efficiency. Additionally, there is a growing focus on expanding access to screening services in underserved communities, ensuring that all women have the opportunity to benefit from early detection, regardless of their geographic or economic circumstances. These trends are driving significant innovation in the field, ensuring that breast cancer screening continues to advance and adapt to the needs of diverse populations.
What Factors Are Fueling Growth in the Breast Cancer Screening Market?
The growth in the breast cancer screening market is fueled by a combination of technological advancements, evolving healthcare practices, and increasing awareness. One of the key drivers is the ongoing innovation in screening technologies, such as the widespread adoption of 3D mammography and the integration of AI in imaging, which are improving the accuracy and reliability of cancer detection. The rising incidence of breast cancer, especially among aging populations, is also contributing to the increased demand for screening services, as early detection is critical for improving survival rates. Furthermore, the trend towards personalized medicine is expanding the market for genetic testing and other risk assessment tools, as more screening programs are tailored to individual risk profiles. Public health initiatives and awareness campaigns have significantly boosted participation rates in regular screening, particularly in regions where established healthcare systems provide easy access to these services. These factors are collectively supporting the robust expansion of the breast cancer screening market, as it continues to evolve in response to technological advancements and the changing needs of the global population.
SELECT PLAYERS
A&G Pharmaceutical, Inc.; Agendia NV; Biocrates Life Sciences AG; Hologic, Inc.; Metabolomic Technologies Inc.; Myriad Genetics, Inc.; Quest Diagnostics, Inc.; Roche Diagnostics
SEGMENTS
» Test Type (Imaging Test, Immunohistochemistry Test, Genetic Test, Blood Marker Test)
GEOGRAPHIES
» World » United States » Canada » Japan » China » Europe » France » Germany » Italy » United Kingdom » Spain » Russia » and Rest of Europe » Asia-Pacific » Australia » India » South Korea » and Rest of Asia-Pacific » Latin America » Argentina » Brazil » Mexico » and Rest of Latin America » Middle East » Iran » Israel » Saudi Arabia » United Arab Emirates » and Rest of Middle East » and Africa
TABLE OF CONTENTS
I. METHODOLOGY |
II. EXECUTIVE SUMMARY |
1. MARKET OVERVIEW |
Influencer Market Insights |
World Market Trajectories |
Breast Cancer Screening – Global Key Competitors Percentage Market Share in 2024 (E) |
Competitive Market Presence - Strong/Active/Niche/Trivial for 42 Players Worldwide in 2024 (E) |
2. FOCUS ON SELECT PLAYERS |
3. MARKET TRENDS & DRIVERS |
Rising Incidence of Breast Cancer Propels Demand for Advanced Screening Methods |
Increased Awareness and Early Detection Efforts Expand Addressable Market Opportunity |
Advancements in Imaging Techniques Strengthen the Business Case for Enhanced Screening Tools |
Growing Adoption of 3D Mammography Spurs Growth in Breast Cancer Screening |
Rising Demand for Non-Invasive Screening Options Generates Need for Advanced Diagnostic Methods |
Expansion of National Screening Programs Sustains Growth in the Breast Cancer Screening Market |
Advances in Genetic Testing Propel Innovation in Risk-Based Screening Strategies |
Rising Demand for Portable and Accessible Screening Devices Expands Market for Mobile Screening Solutions |
4. GLOBAL MARKET PERSPECTIVE |
World Breast Cancer Screening Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030 |
World Recent Past, Current & Future Analysis for Breast Cancer Screening by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR |
World Historic Review for Breast Cancer Screening by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
World 16-Year Perspective for Breast Cancer Screening by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030 |
World Recent Past, Current & Future Analysis for Imaging Test by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR |
World Historic Review for Imaging Test by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
World 16-Year Perspective for Imaging Test by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030 |
World Recent Past, Current & Future Analysis for Immunohistochemistry Test by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR |
World Historic Review for Immunohistochemistry Test by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
World 16-Year Perspective for Immunohistochemistry Test by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030 |
World Recent Past, Current & Future Analysis for Genetic Test by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR |
World Historic Review for Genetic Test by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
World 16-Year Perspective for Genetic Test by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030 |
World Recent Past, Current & Future Analysis for Blood Marker Test by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR |
World Historic Review for Blood Marker Test by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
World 16-Year Perspective for Blood Marker Test by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030 |
III. MARKET ANALYSIS |
UNITED STATES |
Breast Cancer Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E) |
USA Recent Past, Current & Future Analysis for Breast Cancer Screening by Test Type - Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
USA Historic Review for Breast Cancer Screening by Test Type - Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
USA 16-Year Perspective for Breast Cancer Screening by Test Type - Percentage Breakdown of Value Sales for Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test for the Years 2014, 2024 & 2030 |
CANADA |
Canada Recent Past, Current & Future Analysis for Breast Cancer Screening by Test Type - Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
Canada Historic Review for Breast Cancer Screening by Test Type - Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
Canada 16-Year Perspective for Breast Cancer Screening by Test Type - Percentage Breakdown of Value Sales for Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test for the Years 2014, 2024 & 2030 |
JAPAN |
Breast Cancer Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E) |
Japan Recent Past, Current & Future Analysis for Breast Cancer Screening by Test Type - Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
Japan Historic Review for Breast Cancer Screening by Test Type - Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
Japan 16-Year Perspective for Breast Cancer Screening by Test Type - Percentage Breakdown of Value Sales for Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test for the Years 2014, 2024 & 2030 |
CHINA |
Breast Cancer Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E) |
China Recent Past, Current & Future Analysis for Breast Cancer Screening by Test Type - Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
China Historic Review for Breast Cancer Screening by Test Type - Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
China 16-Year Perspective for Breast Cancer Screening by Test Type - Percentage Breakdown of Value Sales for Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test for the Years 2014, 2024 & 2030 |
EUROPE |
Breast Cancer Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E) |
Europe Recent Past, Current & Future Analysis for Breast Cancer Screening by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR |
Europe Historic Review for Breast Cancer Screening by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
Europe 16-Year Perspective for Breast Cancer Screening by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030 |
Europe Recent Past, Current & Future Analysis for Breast Cancer Screening by Test Type - Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
Europe Historic Review for Breast Cancer Screening by Test Type - Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
Europe 16-Year Perspective for Breast Cancer Screening by Test Type - Percentage Breakdown of Value Sales for Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test for the Years 2014, 2024 & 2030 |
FRANCE |
Breast Cancer Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E) |
France Recent Past, Current & Future Analysis for Breast Cancer Screening by Test Type - Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
France Historic Review for Breast Cancer Screening by Test Type - Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
France 16-Year Perspective for Breast Cancer Screening by Test Type - Percentage Breakdown of Value Sales for Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test for the Years 2014, 2024 & 2030 |
GERMANY |
Breast Cancer Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E) |
Germany Recent Past, Current & Future Analysis for Breast Cancer Screening by Test Type - Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
Germany Historic Review for Breast Cancer Screening by Test Type - Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
Germany 16-Year Perspective for Breast Cancer Screening by Test Type - Percentage Breakdown of Value Sales for Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test for the Years 2014, 2024 & 2030 |
ITALY |
Italy Recent Past, Current & Future Analysis for Breast Cancer Screening by Test Type - Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
Italy Historic Review for Breast Cancer Screening by Test Type - Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
Italy 16-Year Perspective for Breast Cancer Screening by Test Type - Percentage Breakdown of Value Sales for Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test for the Years 2014, 2024 & 2030 |
UNITED KINGDOM |
Breast Cancer Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E) |
UK Recent Past, Current & Future Analysis for Breast Cancer Screening by Test Type - Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
UK Historic Review for Breast Cancer Screening by Test Type - Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
UK 16-Year Perspective for Breast Cancer Screening by Test Type - Percentage Breakdown of Value Sales for Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test for the Years 2014, 2024 & 2030 |
SPAIN |
Spain Recent Past, Current & Future Analysis for Breast Cancer Screening by Test Type - Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
Spain Historic Review for Breast Cancer Screening by Test Type - Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
Spain 16-Year Perspective for Breast Cancer Screening by Test Type - Percentage Breakdown of Value Sales for Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test for the Years 2014, 2024 & 2030 |
RUSSIA |
Russia Recent Past, Current & Future Analysis for Breast Cancer Screening by Test Type - Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
Russia Historic Review for Breast Cancer Screening by Test Type - Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
Russia 16-Year Perspective for Breast Cancer Screening by Test Type - Percentage Breakdown of Value Sales for Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test for the Years 2014, 2024 & 2030 |
REST OF EUROPE |
Rest of Europe Recent Past, Current & Future Analysis for Breast Cancer Screening by Test Type - Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
Rest of Europe Historic Review for Breast Cancer Screening by Test Type - Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
Rest of Europe 16-Year Perspective for Breast Cancer Screening by Test Type - Percentage Breakdown of Value Sales for Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test for the Years 2014, 2024 & 2030 |
ASIA-PACIFIC |
Breast Cancer Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E) |
Asia-Pacific Recent Past, Current & Future Analysis for Breast Cancer Screening by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR |
Asia-Pacific Historic Review for Breast Cancer Screening by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
Asia-Pacific 16-Year Perspective for Breast Cancer Screening by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030 |
Asia-Pacific Recent Past, Current & Future Analysis for Breast Cancer Screening by Test Type - Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
Asia-Pacific Historic Review for Breast Cancer Screening by Test Type - Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
Asia-Pacific 16-Year Perspective for Breast Cancer Screening by Test Type - Percentage Breakdown of Value Sales for Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test for the Years 2014, 2024 & 2030 |
AUSTRALIA |
Breast Cancer Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E) |
Australia Recent Past, Current & Future Analysis for Breast Cancer Screening by Test Type - Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
Australia Historic Review for Breast Cancer Screening by Test Type - Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
Australia 16-Year Perspective for Breast Cancer Screening by Test Type - Percentage Breakdown of Value Sales for Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test for the Years 2014, 2024 & 2030 |
INDIA |
Breast Cancer Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E) |
India Recent Past, Current & Future Analysis for Breast Cancer Screening by Test Type - Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
India Historic Review for Breast Cancer Screening by Test Type - Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
India 16-Year Perspective for Breast Cancer Screening by Test Type - Percentage Breakdown of Value Sales for Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test for the Years 2014, 2024 & 2030 |
SOUTH KOREA |
South Korea Recent Past, Current & Future Analysis for Breast Cancer Screening by Test Type - Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
South Korea Historic Review for Breast Cancer Screening by Test Type - Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
South Korea 16-Year Perspective for Breast Cancer Screening by Test Type - Percentage Breakdown of Value Sales for Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test for the Years 2014, 2024 & 2030 |
REST OF ASIA-PACIFIC |
Rest of Asia-Pacific Recent Past, Current & Future Analysis for Breast Cancer Screening by Test Type - Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
Rest of Asia-Pacific Historic Review for Breast Cancer Screening by Test Type - Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
Rest of Asia-Pacific 16-Year Perspective for Breast Cancer Screening by Test Type - Percentage Breakdown of Value Sales for Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test for the Years 2014, 2024 & 2030 |
LATIN AMERICA |
Breast Cancer Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E) |
Latin America Recent Past, Current & Future Analysis for Breast Cancer Screening by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR |
Latin America Historic Review for Breast Cancer Screening by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
Latin America 16-Year Perspective for Breast Cancer Screening by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030 |
Latin America Recent Past, Current & Future Analysis for Breast Cancer Screening by Test Type - Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
Latin America Historic Review for Breast Cancer Screening by Test Type - Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
Latin America 16-Year Perspective for Breast Cancer Screening by Test Type - Percentage Breakdown of Value Sales for Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test for the Years 2014, 2024 & 2030 |
ARGENTINA |
Argentina Recent Past, Current & Future Analysis for Breast Cancer Screening by Test Type - Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
Argentina Historic Review for Breast Cancer Screening by Test Type - Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
Argentina 16-Year Perspective for Breast Cancer Screening by Test Type - Percentage Breakdown of Value Sales for Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test for the Years 2014, 2024 & 2030 |
BRAZIL |
Brazil Recent Past, Current & Future Analysis for Breast Cancer Screening by Test Type - Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
Brazil Historic Review for Breast Cancer Screening by Test Type - Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
Brazil 16-Year Perspective for Breast Cancer Screening by Test Type - Percentage Breakdown of Value Sales for Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test for the Years 2014, 2024 & 2030 |
MEXICO |
Mexico Recent Past, Current & Future Analysis for Breast Cancer Screening by Test Type - Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
Mexico Historic Review for Breast Cancer Screening by Test Type - Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
Mexico 16-Year Perspective for Breast Cancer Screening by Test Type - Percentage Breakdown of Value Sales for Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test for the Years 2014, 2024 & 2030 |
REST OF LATIN AMERICA |
Rest of Latin America Recent Past, Current & Future Analysis for Breast Cancer Screening by Test Type - Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
Rest of Latin America Historic Review for Breast Cancer Screening by Test Type - Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
Rest of Latin America 16-Year Perspective for Breast Cancer Screening by Test Type - Percentage Breakdown of Value Sales for Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test for the Years 2014, 2024 & 2030 |
MIDDLE EAST |
Breast Cancer Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E) |
Middle East Recent Past, Current & Future Analysis for Breast Cancer Screening by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR |
Middle East Historic Review for Breast Cancer Screening by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
Middle East 16-Year Perspective for Breast Cancer Screening by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030 |
Middle East Recent Past, Current & Future Analysis for Breast Cancer Screening by Test Type - Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
Middle East Historic Review for Breast Cancer Screening by Test Type - Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
Middle East 16-Year Perspective for Breast Cancer Screening by Test Type - Percentage Breakdown of Value Sales for Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test for the Years 2014, 2024 & 2030 |
IRAN |
Iran Recent Past, Current & Future Analysis for Breast Cancer Screening by Test Type - Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
Iran Historic Review for Breast Cancer Screening by Test Type - Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
Iran 16-Year Perspective for Breast Cancer Screening by Test Type - Percentage Breakdown of Value Sales for Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test for the Years 2014, 2024 & 2030 |
ISRAEL |
Israel Recent Past, Current & Future Analysis for Breast Cancer Screening by Test Type - Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
Israel Historic Review for Breast Cancer Screening by Test Type - Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
Israel 16-Year Perspective for Breast Cancer Screening by Test Type - Percentage Breakdown of Value Sales for Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test for the Years 2014, 2024 & 2030 |
SAUDI ARABIA |
Saudi Arabia Recent Past, Current & Future Analysis for Breast Cancer Screening by Test Type - Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
Saudi Arabia Historic Review for Breast Cancer Screening by Test Type - Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
Saudi Arabia 16-Year Perspective for Breast Cancer Screening by Test Type - Percentage Breakdown of Value Sales for Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test for the Years 2014, 2024 & 2030 |
UNITED ARAB EMIRATES |
UAE Recent Past, Current & Future Analysis for Breast Cancer Screening by Test Type - Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
UAE Historic Review for Breast Cancer Screening by Test Type - Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
UAE 16-Year Perspective for Breast Cancer Screening by Test Type - Percentage Breakdown of Value Sales for Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test for the Years 2014, 2024 & 2030 |
REST OF MIDDLE EAST |
Rest of Middle East Recent Past, Current & Future Analysis for Breast Cancer Screening by Test Type - Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
Rest of Middle East Historic Review for Breast Cancer Screening by Test Type - Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
Rest of Middle East 16-Year Perspective for Breast Cancer Screening by Test Type - Percentage Breakdown of Value Sales for Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test for the Years 2014, 2024 & 2030 |
AFRICA |
Breast Cancer Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E) |
Africa Recent Past, Current & Future Analysis for Breast Cancer Screening by Test Type - Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
Africa Historic Review for Breast Cancer Screening by Test Type - Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
Africa 16-Year Perspective for Breast Cancer Screening by Test Type - Percentage Breakdown of Value Sales for Imaging Test, Immunohistochemistry Test, Genetic Test and Blood Marker Test for the Years 2014, 2024 & 2030 |
IV. COMPETITION |
PREVIEW REPORT
Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.
What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.
Privacy queries: Privacy@StrategyR.com
DIFFERENTIATORS
Our research offerings primarily draw upon unique perspectives of participating executives and their experiences in operating and strategy roles. These geo-focused insights enrich our projects .
What we are NOT - Our reports are not editorial exercises of remote analysts’ secondary source fed content that predominantly flood today’s off-the-shelf market report business. (A review of 262 publishers).
WHAT SETS US APART
FULL STACK DATA ACCESS
- Primary Research Cluster Data
- Influencer Engagement Stats
- Evidence of Primary Research
- List of Companies Engaged
- Hundreds of Pages of Research
- Peer Collaborative Interactions
- Enterprise Data Exchanges
- MarketGlassTM Platform Insider
- Geographic Pricing Dynamics
- Competitive Shares by Country
- Brand Curation & Insights
- Domain Expert Pool
Program Transparency: Clients have access to engagement stats of companies and executives. Clients may commission third-party audits of our influencer engagements at their expense.
Primary Research: We have a very successful incentive driven primary research program presenting a rich experience to participating executives. Featured company executives can sign up for a complimentary.
Collaborative Intelligence: Our platform presents a unique features for executives to collaborate with peers across geographies and participate on various product or regional perspectives for a collective unified insider project experience.
Global Brand Intelligence: We present competitive brand intelligence at the company level for players worldwide. Executives from brand owner companies participate to curate each brand for relevance and market presence.
Bespoke Updates: Our peer-to-peer online interactive platform enables client companies to build upon our project data stacks to build bespoke editions for internal sharing and use. Client company can build one complimentary update per year and unlimited updates for additional fee. Bespoke updates are fulfilled within a two-day turnaround.
Enterprise EcoConnect: Discretely bounce off queries to participant pool of executives. We can reach out to our participant pool based on specifics of geographic or domain acumen.
Renowned Support: We pride in our commitment to provide support to our clients. We go beyond the scope of the study to get you timely answers.
Complimentary Updates: Unlike the industry’s published PDF’s that are frozen in time from date of release, our research programs are ongoing and dynamic. Our reports are updated whenever there’s a major event impacting the marketplace. Your license offers seamless updates for one year.
No Fluff: We offer our clients the best CX with clean easy to read content. No verbose fluff. We offer clients full access to the entire stack of hundreds of pages of secondary research feeds used in our project via our online MarketGlass portal.